General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-14 | 2024-09 | 1.07 | N/A | N/A | N/A |
2024-07-25 | 2024-06 | 0.96 | 0.99 | 0.03 | 3.13% |
2024-04-25 | 2024-03 | 0.95 | 1.03 | 0.08 | 8.42% |
2024-02-08 | 2023-12 | 0.74 | 0.73 | -0.01 | -1.35% |
2023-11-09 | 2023-09 | 0.8 | 0.87 | 0.07 | 8.75% |
2023-07-28 | 2023-06 | 0.97 | 1.08 | 0.11 | 11.34% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-24 | Jefferies | Upgrade | Hold | Buy |
2023-09-07 | Erste Group | Downgrade | Buy | Hold |
2023-07-31 | BMO Capital | Upgrade | Outperform | Outperform |
2023-05-25 | Argus Research | Upgrade | Buy | Buy |
2023-04-12 | Argus Research | Upgrade | Buy | |
2023-01-04 | BMO Capital | Upgrade | Outperform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2020-12-15 | Ashley (Euan) | 700.00 | Bought | |
2017-09-24 | Bohen (Sean) | 24.77K | Bought | |
2019-04-28 | Eldracher (Deborah DiSanzo) | 1000 | Bought | |
2019-04-28 | McCoy (Sherilyn D) | 2.47K | Bought | |
2021-12-12 | Mok (Tony) | 4.00K | Bought | |
2022-05-04 | Rummelt (Andreas) | 0.00 | Sold |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Price (T.Rowe) Associates Inc | 52.85M | 3.78B | 2.01% |
2023-06-29 | Wellington Management Group, LLP | 49.13M | 3.52B | 1.87% |
2023-06-29 | Primecap Management Company | 44.08M | 3.15B | 1.68% |
2023-06-29 | Capital International Investors | 38.34M | 2.74B | 1.46% |
2023-06-29 | FMR, LLC | 22.82M | 1.63B | 0.87% |
2023-06-29 | Jennison Associates LLC | 21.81M | 1.56B | 0.83% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard/Primecap Fund | 25.66M | 1.84B | 0.98% |
2023-09-29 | Washington Mutual Investors Fund | 22.46M | 1.52B | 0.86% |
2023-05-30 | Vanguard/Wellington Fund Inc. | 17.32M | 1.27B | 0.66% |
2023-09-29 | American Mutual Fund Inc | 11.35M | 768.66M | 0.43% |
2023-08-30 | Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF | 10.03M | 680.32M | 0.38% |
2023-06-29 | Price (T.Rowe) Health Sciences Fund | 7.02M | 502.22M | 0.27% |
Dividend | Date |
---|---|
0.49 | 2024-08-09 |
0.985 | 2024-02-22 |
0.465 | 2023-08-10 |
0.965 | 2023-02-23 |
0.455 | 2022-08-11 |
0.965 | 2022-02-24 |
Split | Date |
---|---|
2 : 1 | 2015-07-27 |
3 : 1 | 1998-04-08 |
https://www.inverse.com/mind-body/oxford-vaccine-trial-results-tease-a-huge-benefit
THE OXFORD VACCINE REVEALS 1 'PROVOCATIVE' FINDING OTHER TRIALS ARE MISSING
"The light is getting brighter at the end of the tunnel."
Iryna Veklich/Getty Images
EMMA BETUEL
3 HOURS AGO
NOVEMBER HAS BEEN A HUGE MONTH FOR VACCINE NEWS, and promising vaccine results continue to roll in. On Monday, the University of Oxford and the drugmaker AstraZeneca released exciting interim results from a Phase 3 trial of another coronavirus vaccine candidate, indicating two different levels of efficacy depending on the dosage.
The vaccine was 62 percent effective in preventing disease participants given two standard doses of the vaccine, one month apart. Meanwhile, the vaccine was 90 percent effective in participants who received a half dose and then a full dose one month later. The results were based on 131 Covid-19 cases
The Oxford vaccine news makes for a fortunate pattern: For the past three weeks, Mondays have meant vaccine announcements. This announcement follows those made by the drugmakers Pfizer and Moderna.
The 90 percent figure, achieved with the half dose followed by a full dose, would put the Oxford vaccine in league with Moderna’s vaccine candidate (94.5 percent effective) and Pfizer’s vaccine (95 percent effective).
But unlike the other leading vaccine candidates, the Oxford vaccine may prove to be advantageous in three unique ways:
Early data suggests it offers a glimmer of hope for controlling the spread of the virus.
It may be cheaper: about $2.50 per dose compared to Pfizer’s $20 and Moderna's $15 to $25 per dose.
It will probably prove easier to transport, though the dosage scheme could pose problems later on.
It's the potential for controlling the spread of the virus that makes the Oxford vaccine especially different, based on these early results. Other vaccine trials have not reported any data on how the vaccines perform in the face of asymptomatic cases. The Oxford vaccine press release suggests there were fewer asymptomatic infections among those who got the vaccine.
Well
Messenger RNA.... PFE& MRNA using a brand new method.
AZN using a well known method.
Guys.... patient will be doing well with us.
I’m not the smart guy in the world but I’m sure that AZN have better vaccine I think that more and more contracts with AZN and governments all over the world will be made in the next week
Now it a foggy morning.Here come the ️!
A normal flu vaccine is just over 50% effective. 70% sounds good to me. Go AZN
Guys.
We are not in Olomouc games. We talking science 🧪.
AZN give much more details to public
OMG. It is SOOO clear
In one of the 2 procedures they achieve 90 % of efficacy.
So. They will go to FDA with this procedure!
70% is the average between the 2 BUT WHO CARE about it!!!
We talking about 90% efficacy. It’s clear to me that AZN has the best one so far
Now it’s a foggy picture
Wait a day or 3 and you will see the BIG BANG !!
When the fog will gone the picture will be very clear
90% efficacy
Easy transport
Easy storage
Cheap price.
I think we have a winner here.
Can some one correct me ?
Guys why the media focused on one regiment??
It’s so clear ! AZN say that the other regiment is 90% ! WOW!
Am I stupid ? They made 2 regiment
One of them reached out to 90 % efficacy!
Am I missing something???
If it’s correct so we have here a winner !
Read this:
However, AstraZeneca (AZN) says that a smaller dosing regimen of 1.5 shots instead of two is 90% efficient. Moreover, the material can be stored in regular fridge temperature and the firm says it can produce three billion doses next year.
90% !! After half and one dose !
https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html
One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen (n=8,895) showed 62% efficacy when given as two full doses at least one month apart. The combined analysis from both dosing regimens (n=11,636) resulted in an average efficacy of 70%. All results were statistically significant (p<=0.0001). More data will continue to accumulate and additional analysis will be conducted, refining the efficacy reading and establishing the duration of protection.
Guys
It’s 90% of efficacy. Am I wrong??
90% efficacy after the first dose.
LONDON (Reuters) - AstraZeneca said on Monday its vaccine for the novel coronavirus, developed along with the University of Oxford, could be around 90% effective under one dosing regimen.
I’m worng ?
LONDON (Reuters) - AstraZeneca said on Monday its vaccine for the novel coronavirus, developed along with the University of Oxford, could be around 90% effective under one dosing regimen.
“This vaccine’s efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency,” Pascal Soriot, Astra’s chief executive, said in a statement.
The British drugmaker’s preliminary trial results mark a fresh breakthrough in the fight against a pandemic that has killed nearly 1.4 million people and roiled the global economy.
AstraZeneca, Oxford Covid-19 Vaccine Up to 90% Effective in Late-Stage Trials
Efficacy ranged from 62% to 90%, depending on dosage
1 one shot 1.5 doses give us 90%!!!!
Guys if this is correct we have a winner here !!!
Well... I read what they just published !!!
Coronavirus vaccine: AstraZeneca says smaller dosing regime reaches 90% efficacy.
Coronavirus vaccine: AstraZeneca says smaller dosing regime reaches 90% efficacy!!!!!!
Wow. It’s sound great !!!!
So
Tomorrow is the day?
When AZN will publish their efficacy ?
Let’s pray for better world. Ha?
$AZN Big news in Australia about AZN
Also... the level of protection on those group have the same protection like the young.
. WOW. !!! This is a GREAT evidence we are talking with golden egg here.
Nice day !
Guys
See how AZN present fact
First it’s not a ad statement all over TV. It’s a LANCET article one of the most highly recommended scientific research in the world
Second
560 people
160 18-52
160 52-70 some people have been with existing illness
240 - 70 and above. The same.
The same amount of protection in all those 3 grips.
also
So the next step will be moderna 98% ?
Guys. If a vaccine is above 75% game is over because temperature has been in the most important part of the the game.
On another note.
Beside COVID there is another’s innovations.
Some pay is attention to this: ? :
“ AstraZeneca’s P2Y12 receptor antagonist Brilinta reduced the rate of stroke and death in a prespecified, high-risk subgroup, according to new analysis of the phase III THALES trial.”
AstraZeneca’s Brilinta (ticagrelor) reduced the composite of stroke and death in patients with head and neck artery atherosclerosis who had an acute ischaemic stroke or transient ischaemic attack, according to new clinical trial data.
Wow. That’s a great news for AZN!
-3% in London
'I Love The Smell Of Napalm In The Morning”
Well...
Prepare for bad bad news .
But who need money. ?!!!!
May god help all !
️